Sigyn Therapeutics files Form 12b-25 for late 10-K

Sigyn Therapeutics, Inc. notified the SEC that it could not timely file its Form 10-K for the period ended December 31, 2025.

Rhea-AI Filing Summary

Sigyn Therapeutics, Inc. notified the SEC that it could not timely file its Form 10-K for the period ended December 31, 2025. The company states that compilation, dissemination and review of required information made timely filing impracticable and will file the Form 10-K no later than five days after its original due date. The notification is signed by James Joyce, Chief Executive Officer, on March 31, 2026.

Insights

Corporate Filings Analyst

Routine late‑filing notice citing resource and timing constraints.

The Form 12b-25 for Sigyn Therapeutics states the company could not complete the Form 10-K for the period ended December 31, 2025 without unreasonable effort or expense due to compilation and review time constraints. The company commits to file the report within five calendar days of the original due date.

Timing and content of the eventual 10‑K will determine material investor impact; current disclosure is an administrative notification and does not itself report operating results or new financial metrics. Subsequent filings should be reviewed for any material changes to results or additional qualifiers.

Key Figures

Report period end: December 31, 2025 Notice signed: March 31, 2026 Filing cure period: 5 days +1 more

4 metrics

Report period end December 31, 2025 Form 10-K reporting period

Notice signed March 31, 2026 Signature date on Form 12b-25

Filing cure period 5 days Commitment to file the Form 10-K within five days after original due date

Form expires September 30, 2028 Form 12b-25 expiration date printed on form

Key Terms

Rule 12b-25, Form 10-K, notification of late filing

3 terms

Rule 12b-25 regulatory

"If the subject report could not be filed without unreasonable effort or expense"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-K regulatory

"For Period Ended: December 31, 2025"

A Form 10-K is a comprehensive report that publicly traded companies are required to file annually with regulators. It provides a detailed overview of a company's financial health, operations, and risks, similar to a detailed health report. Investors use this information to assess the company's performance and make informed decisions about buying or selling its stock.

notification of late filing regulatory

"NOTIFICATION OF LATE FILING"

A notification of late filing is a formal public statement that a company failed to submit a required regulatory report (for example, quarterly or annual financial statements) by the deadline. It matters to investors because missed filings can signal accounting, operational, or governance problems, may lead to fines or trading restrictions, and increases uncertainty about the company's transparency—like a public “we missed the deadline” flag that raises risk for shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sigyn Therapeutics (SIGY) file with the SEC?

Sigyn Therapeutics filed a Form 12b-25 notifying the SEC of a late Form 10-K. The notice states the Form 10-K for year ended December 31, 2025 will be filed within five days of the original due date.

Why did SIGY miss its Form 10-K deadline?

The company cited time constraints from compiling, disseminating and reviewing required information. It said completing the 10-K by the original deadline would have required unreasonable effort and expense.

When did Sigyn Therapeutics sign the late‑filing notice?

The notification was signed by James Joyce, Chief Executive Officer on March 31, 2026, certifying the company’s intent to file the Form 10-K promptly.

How long does SIGY expect to delay the Form 10-K filing?

Sigyn Therapeutics states it will file the Form 10-K no later than five days after the original due date, per Rule 12b-25(b) timing allowances for quarterly reports.

Does the Form 12b-25 disclose financial changes for SIGY?

No. The filing explains a timing delay and does not provide earnings, revenue or other financial metrics. Material changes, if any, will appear in the subsequently filed Form 10-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 05:20 PM EDT Learn about SEC filing dates

		OMB APPROVAL
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB Number:	3235-0058
		Expires:	September 30, 2028
		Estimated average burden hours per response 2.50
	FORM 12b-25	SEC FILE NUMBER
			CUSIP NUMBER
	NOTIFICATION OF LATE FILING

(Check one):	☒ Form 10-K	☐ Form 20-F	☐ Form 11-K
	☐ Form 10-Q	☐ Form 10-D	☐ Form N-CEN	☐ Form N-CSR

For Period Ended: December 31, 2025

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q

For the Transition Period Ended:____________________________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Sigyn Therapeutics, Inc.

Full Name of Registrant

Former Name if Applicable

2301 Historic Decatur Road, Suite 100

Address of Principal Executive Office (Street and Number)

San Diego, California 92106

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The compilation, dissemination and review of the information required to be presented in the Form 10-Q has imposed time constraints that have rendered timely filing of the Form 10-Q impracticable without undue hardship and expense to the registrant. The registrant undertakes the responsibility to file such quarterly report no later than five days after its original due date.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

James Joyce		619		353-0800
(Name)		(Area Code)		(Telephone Number)

	(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
		☒ Yes ☐ No

	(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
		☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2 of 3

SIGYN THERAPEUTICS, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	March 31, 2026		By:	/s/ James Joyce
			Name:	James Joyce
			Title:	Chief Executive Officer

INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the Form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

3 of 3